Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors

Advanced Solid Tumors Clinical Trial

Official title:
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-706 as Monotherapy and in Combination With Budigalimab (ABBV-181), Carboplatin, or Cisplatin in Adult Subjects With Advanced Solid Tumors

Status Recruiting

Clinical Trial Summary

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-706 as a monotherapy and in combination with budigalimab, carboplatin, or cisplatin. ABBV-706 is an investigational drug being developed for the treatment of small cell lung cancer (SCLC), high-grade central nervous system (CNS) tumors and high-grade neuroendocrine carcinomas (NECs). There are multiple treatment arms in this study. Participants will either receive ABBV-706 as a single agent or in combination with budigalimab (another investigational drug), carboplatin or cisplatin at different doses. Approximately 350 adult participants will be enrolled in the study across sites worldwide. In part 1 (dose escalation), ABBV-706 will be intravenously infused in escalating doses as a monotherapy until the maximum tolerated dose (MTD) is determined in participants with SCLC, high-grade CNS tumors, and high-grade NECs. In part 2, multiple doses will be selected from Part 1 and SCLC participants will be assigned to one of these doses in a randomized fashion to determine the recommended Phase 2 dose. In Part 3a, participants with SCLC or NECs will receive ABBV-706 in combination with budigalimab intravenously every 3 weeks. In Part 3b participants with SCLC or NECs will receive ABBV-706 in combination with either carboplatin or cisplatin intravenously. In Part 4a, participants with CNS tumors will receive ABBV-706 intravenously at a dose determined from Part 1. In Part 4b, participants with NECs will receive ABBV-706 intravenously at a dose selected from Part 1. The estimated duration of the study is up to 3 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05599984
Study type	Interventional
Source	AbbVie
Contact	ABBVIE CALL CENTER
Phone	844-663-3742
Email	abbvieclinicaltrials@abbvie.com
Status	Recruiting
Phase	Phase 1
Start date	December 5, 2022
Completion date	May 17, 2027

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04972981` - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors	Phase 1
Completed	`NCT05086822` - A Study of Irinotecan Hydrochloride Liposome in Advanced Solid Tumors	Phase 1
Completed	`NCT03260322` - A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors	Phase 1
Completed	`NCT02526017` - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers	Phase 1
Recruiting	`NCT06040541` - Study of RMC-9805 in Participants With KRASG12D-Mutant Solid Tumors	Phase 1
Recruiting	`NCT05862831` - Clinical Study of PM1003 in Phase I/IIa Treatment of Advanced Malignant Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT03641794` - Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Healthy Volunteers	Phase 1
Terminated	`NCT03665129` - IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors	Phase 1
Not yet recruiting	`NCT06413680` - A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies	Phase 1/Phase 2
Recruiting	`NCT05914116` - A Study of DB-1311 in Advanced/Metastatic Solid Tumors	Phase 1/Phase 2
Completed	`NCT01693562` - A Phase 1/2 Study to Evaluate MEDI4736	Phase 1/Phase 2
Recruiting	`NCT04387916` - A Study of KC1036 in Patients With Advanced Solid Tumors	Phase 1
Completed	`NCT04095273` - Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug	Phase 1
Not yet recruiting	`NCT03692520` - Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SCT200 in Patients With Advanced Solid Tumors	Phase 1
Completed	`NCT02997176` - An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800)	Phase 1
Recruiting	`NCT04446260` - A Study of SHR-A1811 in Subjects With Advanced Malignant Solid Tumors	Phase 1
Recruiting	`NCT06239155` - A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors	Phase 1/Phase 2
Terminated	`NCT02253992` - An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma	Phase 1/Phase 2
Recruiting	`NCT06076291` - An Open-label Study of SG1827 in Subjects With Advanced Solid Tumors	Phase 1
Completed	`NCT03545971` - A Study of IBI310 for the Treatment of Patients With Advanced Solid Tumors.	Phase 1